Ascendis Pharma A/S (NASDAQ:ASND) PT Lowered to $170.00

Ascendis Pharma A/S (NASDAQ:ASND) had its target price trimmed by Cantor Fitzgerald from $173.00 to $170.00 in a research report report published on Wednesday morning, Benzinga reports. The firm currently has an overweight rating on the biotechnology company’s stock. Cantor Fitzgerald also issued estimates for Ascendis Pharma A/S’s FY2024 earnings at ($6.59) EPS.

ASND has been the subject of several other reports. JPMorgan Chase & Co. boosted their target price on shares of Ascendis Pharma A/S from $170.00 to $174.00 and gave the company an overweight rating in a research report on Wednesday, August 21st. The Goldman Sachs Group raised their target price on Ascendis Pharma A/S from $170.00 to $195.00 and gave the company a buy rating in a report on Tuesday, August 13th. StockNews.com cut Ascendis Pharma A/S from a hold rating to a sell rating in a report on Tuesday, August 13th. TD Cowen raised Ascendis Pharma A/S from a hold rating to a buy rating and raised their price objective for the company from $156.00 to $175.00 in a research note on Tuesday, June 25th. Finally, Stifel Nicolaus started coverage on Ascendis Pharma A/S in a research report on Friday, May 31st. They issued a buy rating and a $200.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Ascendis Pharma A/S currently has an average rating of Moderate Buy and an average target price of $187.08.

Ascendis Pharma A/S Stock Up 0.1 %

ASND stock opened at $119.15 on Wednesday. Ascendis Pharma A/S has a 52 week low of $85.29 and a 52 week high of $161.00. The business has a 50-day simple moving average of $134.38 and a 200 day simple moving average of $138.07. The company has a market cap of $6.94 billion, a PE ratio of -12.40 and a beta of 0.63.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vestal Point Capital LP acquired a new stake in shares of Ascendis Pharma A/S in the fourth quarter valued at about $78,719,000. Price T Rowe Associates Inc. MD increased its position in Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after purchasing an additional 336,976 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in Ascendis Pharma A/S by 20.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company’s stock worth $191,346,000 after purchasing an additional 254,749 shares during the last quarter. Acadian Asset Management LLC lifted its position in shares of Ascendis Pharma A/S by 1,461.1% in the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after purchasing an additional 234,446 shares during the period. Finally, Avoro Capital Advisors LLC lifted its position in shares of Ascendis Pharma A/S by 5.8% in the 2nd quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after purchasing an additional 229,995 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.